$Ionis Pharmaceuticals(IONS)$ $Arrowhead Pharmaceuticals(ARWR)$  $Alnylam Pharmaceuticals(ALNY)$  🚨 $IONS Q2 2026: Pipeline Shock Overshadows a Massive Commercial Opportunity ⚠️📉

Ionis delivered one of the most polarising biotech reports of the quarter. Commercial execution remains impressive, with DAWNZERA continuing to gain momentum and TRYNGOLZA now approved for the much larger severe hypertriglyceridaemia (sHTG) market. However, enthusiasm was overshadowed by a major setback after the Phase 3 CARDIO-TTRansform study for eplontersen failed to meet its primary endpoint in the overall ATTR-CM population, removing one of the company’s most anticipated long-term growth catalysts.

The investment case has now shifted from pipeline optimism to commercial execution.

🐂 Bull Case

• sHTG Approval Unlocks a Massive Opportunity: TRYNGOLZA is now FDA approved for severe hypertriglyceridaemia (sHTG), expanding its addressable market from roughly 3,000 familial chylomicronaemia syndrome (FCS) patients to more than one million adults in the U.S. With the Q2 pricing reset now behind it, the company enters H2 with a significantly larger commercial runway.

• DAWNZERA Continues to Impress: DAWNZERA delivered $26 million in Q2 revenue, up 63% sequentially. Strong uptake in the competitive hereditary angioedema (HAE) market demonstrates that Ionis can successfully convert patients from established therapies and execute commercial launches.

• Strong Balance Sheet Supports Growth: Despite repaying $633 million of convertible notes during the quarter, Ionis still ended Q2 with $2.1 billion in cash and short-term investments, providing ample funding for upcoming launches and pipeline development.

🐻 Bear Case

• Pipeline Shock: CARDIO-TTRansform Misses Primary Endpoint: The biggest disappointment of the quarter came when eplontersen failed to achieve the primary composite endpoint in the overall ATTR-CM population. While the monotherapy subgroup showed nominal statistical significance, the broader failure materially weakens one of Ionis’s largest long-term growth opportunities.

• TRYNGOLZA Revenue Collapses: Revenue plunged 81% sequentially from $27 million to just $5 million following the planned wholesale acquisition cost reset. Although management anticipated a temporary decline, achieving FY26 guidance now depends on an exceptionally strong H2 acceleration.

• Execution Risk Increases: Operating expenses climbed 19% YoY to $370 million as the company simultaneously funds multiple launches. If commercial revenue growth falls short, the path towards cash-flow breakeven could become significantly more challenging.

⚖️ Verdict: ⚪ Neutral

The commercial story continues to improve, but the investment thesis has materially changed.

DAWNZERA continues to exceed expectations, TRYNGOLZA now has access to a market exceeding one million patients, and the balance sheet remains robust. However, the ATTR-CM clinical setback removes one of the company’s most valuable long-term growth drivers. I remain neutral until management demonstrates that commercial execution can compensate for the reduced pipeline potential.

Key Themes

🔴🔴 Major Clinical Miss Reshapes the Investment Thesis

The Phase 3 CARDIO-TTRansform trial was expected to validate Ionis’s leadership in ATTR-CM. Instead, the study failed to achieve its primary composite endpoint across the overall patient population. Although management highlighted encouraging monotherapy subgroup data, investors are now questioning whether eplontersen can meaningfully compete against Pfizer’s market-leading franchise and future competitors.

🔴 TRYNGOLZA’s Pricing Reset Creates Short-Term Pain

TRYNGOLZA revenue collapsed from $27 million in Q1 to just $5 million after management deliberately lowered pricing to strengthen payer access ahead of the broader sHTG launch. The strategy prioritises long-term adoption over near-term revenue, but H2 execution must now be nearly flawless to achieve full-year guidance.

🟢 DAWNZERA Continues Building Momentum

DAWNZERA remains one of the brightest spots in the portfolio. Revenue climbed 63% sequentially to $26 million, validating both the product profile and Ionis’s commercial capabilities. Continued momentum could make DAWNZERA one of the company’s fastest-growing assets.

🟢 sHTG Approval Unlocks a Transformational Market

Late June FDA approval fundamentally changes TRYNGOLZA’s opportunity. The product has transitioned from serving an ultra-rare disease to addressing a market exceeding one million adults with severe hypertriglyceridaemia. If commercial adoption accelerates as expected, H2 could mark the beginning of a completely different revenue trajectory.

🟢 Partnership Revenue Continues Supporting Growth

Collaborative revenue reached $133 million during the quarter, helping offset operating losses while funding commercial expansion. Upcoming catalysts, including GSK’s bepirovirsen PDUFA decision in October, provide additional opportunities for meaningful non-dilutive cash inflows.

⚪ Elevated Spending Reflects Growth Investments

Operating expenses increased to $370 million as Ionis prepares multiple commercial launches and late-stage programmes. While expected, investors will closely monitor whether accelerating product revenue can eventually absorb these higher operating costs.

Key KPIs

• Commercial Revenue (excluding royalties): $43 million

Commercial diversification continues improving as DAWNZERA offsets TRYNGOLZA’s temporary pricing disruption.

• SPINRAZA Royalties: $53 million

Royalty income remains remarkably stable, providing a dependable source of cash generation.

• Cash and Short-Term Investments: $2.1 billion

A strong balance sheet continues providing significant financial flexibility despite debt repayment earlier this year.

Guidance

• FY26 Total Revenue: $875 million to $900 million

Maintained. Guidance implies approximately 20% YoY growth after adjusting for last year’s one-off sapablursen upfront payment.

• FY26 TRYNGOLZA Net Product Sales: $100 million to $110 million

Management expects a significant H2 acceleration as sHTG adoption ramps following the pricing reset.

• FY26 DAWNZERA Net Product Sales: $110 million to $120 million

Current momentum suggests this target appears achievable and could prove conservative if patient switching continues at the current pace.

👉❓ Does the ATTR-CM trial failure permanently change your investment thesis on $IONS, or do you believe the commercial opportunity for TRYNGOLZA and DAWNZERA is now the bigger story?

📢 Don’t miss out! Like, Repost, Comment and Follow me for exclusive setups, cutting-edge trends and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market, share ideas and stack those gains together! 🍀

Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀